Edna Scarlett
Duke University(US)
Publications by Year
Research Areas
Gout, Hyperuricemia, Uric Acid, Drug-Induced Adverse Reactions, Urticaria and Related Conditions, COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research
Most-Cited Works
- → Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase(2005)342 cited
- → Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients(2014)263 cited
- → Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout(2007)219 cited
- → Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo(2010)144 cited
- → 1205 COVID-19 vaccine beliefs amongst individuals living with lupus(2021)1 cited
- → FRI0372 Pharmacokinetics and immunogenicity of pegloticase (PL) infused every 3 weeks to treat refractory gout (RG), including in organ transplant recipients (TR)(2012)
- → SOCIAL DRIVERS OF HEALTH IN A LARGE ACADEMIC LUPUS CLINIC(2025)
- → FRI0390 DUKE-3: A 15-week open-label trial of pegloticase in refractory gout including patients with solid organ transplant or prior pegloticase treatment(2012)